Clinical

Dataset Information

0

A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)


ABSTRACT: This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of ABBV-176 for participants with advanced solid tumors likely to express Prolactin Receptor (PRLR). The study will consist of 2 cohorts: Dose Escalation and Expanded Recommended Phase 2 Dose.

DISEASE(S): Colorectal Cancer,Breast Cancer,Neoplasms,Cancer,Advanced Solid Tumors Cancer,Hepatocellular Carcinoma

PROVIDER: 2243822 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2235325 | ecrin-mdr-crc
| 2295725 | ecrin-mdr-crc
| 2184006 | ecrin-mdr-crc
| 2238930 | ecrin-mdr-crc
2021-01-31 | GSE144326 | GEO
2023-12-15 | GSE249542 | GEO
2023-12-15 | GSE249023 | GEO
| 2388532 | ecrin-mdr-crc
2021-09-02 | GSE182994 | GEO
2017-03-07 | GSE89934 | GEO